1. Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians 2021, 71(1).
2. Hackert T, Ulrich A, Buchler MW: Borderline resectable pancreatic cancer. Cancer letters 2016, 375(2):231-237.
3. Speer AG, Thursfield VJ, Torn-Broers Y, Jefford M: Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. The Medical journal of Australia 2012, 196(8):511-515.
4. Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Marechal R, Van Laethem JL, Ducreux M: Current standards and new innovative approaches for treatment of pancreatic cancer. European journal of cancer (Oxford, England : 1990) 2016, 57:10-22.
5. Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, van de Velde CJ, Vahrmeijer AL, Bonsing BA, Mieog JS et al: Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. The British journal of surgery 2019, 106(8):1055-1065.
6. Liu X, Fu Y, Chen Q, Wu J, Gao W, Jiang K, Miao Y, Wei J: Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. BMC Gastroenterol 2018, 18(1):168.
7. Kovac JD, Mayer P, Hackert T, Klauss M: The Time to and Type of Pancreatic Cancer Recurrence after Surgical Resection: Is Prediction Possible? Academic radiology 2019, 26(6):775-781.
8. Adamu M, Nitschke P, Petrov P, Rentsch A, Distler M, Reissfelder C, Welsch T, Saeger HD, Weitz J, Rahbari NN: Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology : official journal of the International Association of Pancreatology (IAP) [et al] (2018), S1424-3903(18)30110-8.
9. Crippa S, Giannone F, Schiavo Lena M, Belfiori G, Partelli S, Tamburrino D, Delpini R, Pagnanelli M, Pecorelli N, Balzano G et al: R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. Ann Surg Oncol 2021, 28(8):4602-4612.
10. Crippa S, Guarneri G, Belfiori G, Partelli S, Pagnanelli M, Gasparini G, Balzano G, Lena MS, Rubini C, Doglioni C et al: Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer. Eur J Surg Oncol 2020, 46(8):1524-1531.
11. Hank T, Hinz U, Tarantino I, Kaiser J, Niesen W, Bergmann F, Hackert T, Buchler MW, Strobel O: Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. The British journal of surgery 2018, 105(9):1171-1181.
12. Crippa S, Ricci C, Guarneri G, Ingaldi C, Gasparini G, Partelli S, Casadei R, Falconi M: Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. Eur J Surg Oncol 2021, 47(6):1258-1266.
13. Dikmen K, Kerem M, Bostanci H, Sare M, Ekinci O: Intra-Operative Frozen Section Histology of the Pancreatic Resection Margins and Clinical Outcome of Patients with Adenocarcinoma of the Head of the Pancreas Undergoing Pancreaticoduodenectomy. Med Sci Monit 2018, 24:4905-4913.
14. Lai CC, Wang SY, Liao CH, Hsu JT, Chiang KC, Yeh TS, Hwang TL, Yeh CN: Surgical Margin Status of Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Radical Intent: Risk Factors for the Survival Impact of Positive Margins. In vivo (Athens, Greece) 2018, 32(6):1591-1597.
15. Cassinotto C, Dohan A, Zogopoulos G, Chiche L, Laurent C, Sa-Cunha A, Cuggia A, Reinhold C, Gallix B: Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. European journal of radiology 2017, 95:33-38.
16. Hong SB, Lee SS, Kim JH, Kim HJ, Byun JH, Hong SM, Song KB, Kim SC: Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. Radiology 2018, 289(3):710-718.
17. Weyhe D, Obonyo D, Uslar VN, Stricker I, Tannapfel A: Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data. PloS one 2021, 16(3):e0248633.
18. Birgin E, Rasbach E, Téoule P, Rückert F, Reissfelder C, Rahbari NN: Impact of intraoperative margin clearance on survival following pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis. Scientific reports 2020, 10(1):22178.
19. Li B, Wang Y, Jiang H, Li B, Shi X, Gao S, Ni C, Zhang Z, Guo S, Xu J et al: Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evaluation of Whole-Mount Histological Slides. Frontiers in oncology 2020, 10:1472.
20. Nam S, Hong Y, Choi YJ, Kang JG: Clinicopathologic Analysis of Lateral Margin Measured by Whole-mount Section in T3 Rectal Cancer. Annals of coloproctology 2020.
21. Schneider M, Hackert T, Strobel O, Büchler MW: Technical advances in surgery for pancreatic cancer. The British journal of surgery 2021, 108(7):777-785.
22. Napoli N, Kauffmann EF, Vistoli F, Amorese G, Boggi U: State of the art of robotic pancreatoduodenectomy. Updates Surg 2021, 73(3):873-880.
23. Kirkegård J, Aahlin EK, Al-Saiddi M, Bratlie SO, Coolsen M, de Haas RJ, den Dulk M, Fristrup C, Harrison EM, Mortensen MB et al: Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. The British journal of surgery 2019, 106(6):756-764.
24. Takagi K, Umeda Y, Yoshida R, Yagi T, Fujiwara T, Zureikat AH, Hogg ME, Koerkamp BG: Surgical training model and safe implementation of robotic pancreatoduodenectomy in Japan: a technical note. World journal of surgical oncology 2021, 19(1):55.
25. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A: Redefining the R1 resection in pancreatic cancer. The British journal of surgery 2006, 93(10):1232-1237.
26. Verbeke CS: Resection margins and R1 rates in pancreatic cancer--are we there yet? Histopathology 2008, 52(7):787-796.
27. Farris AB, Cohen C, Rogers TE, Smith GH: Whole Slide Imaging for Analytical Anatomic Pathology and Telepathology: Practical Applications Today, Promises, and Perils. Archives of pathology & laboratory medicine 2017, 141(4):542-550.
28. Delpero JR, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Autret A, Turrini O, Monges-Ranchin G et al: Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford) 2014, 16(1):20-33.
29. Gebauer F, Tachezy M, Vashist YK, Marx AH, Yekebas E, Izbicki JR, Bockhorn M: Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? World J Surg 2015, 39(2):493-499.
30. Delpero JR, Jeune F, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Adham M, Autret A et al: Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. Annals of surgery 2017, 266(5):787-796.
31. Suraci C, Young K, Dove J, Shabahang M, Blansfield J: Predicting Positive Margins in Pancreatic Head Adenocarcinoma After Neoadjuvant Therapy: Investigating Disparities in Quality Care Using the National Cancer Database. Ann Surg Oncol 2021, 28(3):1595-1601.
32. Hirono S, Kawai M, Okada K, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Yamaue H: Pancreatic neck cancer has specific and oncologic characteristics regarding portal vein invasion and lymph node metastasis. Surgery 2016, 159(2):426-440.
33. O'Sullivan AW, Heaton N, Rela M: Cancer of the uncinate process of the pancreas: surgical anatomy and clinicopathological features. Hepatobiliary & pancreatic diseases international : HBPD INT 2009, 8(6):569-574.
34. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I: Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Therapeutic advances in medical oncology 2021, 13:17588359211045861.
35. Tan X, Sivakumar S, Bednarsch J, Wiltberger G, Kather JN, Niehues J, de Vos-Geelen J, Valkenburg-van Iersel L, Kintsler S, Roeth A et al: Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. Oncogene 2021, 40(5):899-908.
36. Meng Z, Cao M, Zhang Y, Liu Z, Wu S, Wu H: Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. BMC Gastroenterol 2019, 19(1):59.
37. Hishida T, Masai K, Kaseda K, Asakura K, Asamura H: Debulking surgery for malignant tumors: the current status, evidence and future perspectives. Japanese journal of clinical oncology 2021, 51(9):1349-1362.
38. Schmocker RK, Delitto D, Wright MJ, Ding D, Cameron JL, Lafaro KJ, Burns WR, Wolfgang CL, Burkhart RA, He J: Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. J Am Coll Surg 2021, 232(4):405-413.
39. Datta J, Willobee BA, Ryon EL, Shah MM, Drebin JA, Kooby DA, Merchant NB: Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. JAMA surgery 2021, 156(5):489-495.
40. Verbeke C, Lohr M, Karlsson JS, Del Chiaro M: Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. Cancer treatment reviews 2015, 41(1):17-26.
41. Kurata Y, Shiraki T, Ichinose M, Kubota K, Imai Y: Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective. World journal of surgical oncology 2021, 19(1):85.